Ignite Creation Date:
2025-12-18 @ 9:44 AM
Ignite Modification Date:
2025-12-23 @ 10:48 PM
Study NCT ID:
NCT00728013
Status:
None
Last Update Posted:
2008-08-25 00:00:00
First Post:
2008-07-29 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome
Sponsor:
None
Organization:
Study Overview
Official Title:
China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome
Status:
None
Status Verified Date:
2008-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHILLAS
Brief Summary:
The CHILLAS study is planned to evaluate whether intensive treatment with statins for 2 years results in a reduction of cardiovascular events in patients with ACS. A total of 1,600 patients will be randomly assigned to receive intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins) or moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins). Both groups receive dietary counseling. Over a 2-year follow-up period, the primary outcome measure is the time to occurrence of cardiac death, nonfatal acute myocardial infarction, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting, documented unstable angina or severe heart failure requiring emergency hospitalization, and stroke. The planned duration is between December 2006 and December 2009.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: